摘要
蛋白质是药物给药系统发展中用来合成聚合物的天然配体,它们中的一些已经被美国食品药品监督管理局(FDA)认为与药物传输目的的安全性有关。血清蛋白是人体血液中最丰富的蛋白质。对白蛋白为基础的给药载体药物应用的探索的兴趣,尤其是对于化疗药物给药系统,在最近几年有所增加。白蛋白在合成聚合物上具有许多的优点,例如它具有生物相容性、生物降解性、细胞毒性低以及与其他多种药物具有很好的结合能力。微型和纳米载体不仅防止药物活性成分退化,而且提供了一个可控的缓释药物的方式。因为现有的肿瘤化疗药物既不能定位肿瘤细胞,也不能针对特定的肿瘤细胞,药物从载体里面缓慢释放将对把癌细胞内作为目标有帮助。本文旨在提供一个关于白蛋白在肿瘤化疗中作为一个给药载体的药物应用的综述。
关键词: 白蛋白,癌症,化疗,给药,微球体,纳米颗粒
Current Cancer Drug Targets
Title:Bioactive Albumin-Based Carriers for Tumour Chemotherapy
Volume: 14 Issue: 8
Author(s): Yasser Shahzad, Ikram Ullah Khan, Talib Hussain, Alamgeer, Christophe A. Serra, Syed A.A. Rizvi, Minja Gerber and Jeanetta du Plessis
Affiliation:
关键词: 白蛋白,癌症,化疗,给药,微球体,纳米颗粒
摘要: Proteins are posed as the natural counterpart of the synthetic polymers for the development of drug delivery systems and few of them, have been regarded safe for drug delivery purposes by the United States Food and Drug Administration (FDA). Serum albumin is the most abundant protein in human blood. Interest in the exploration of pharmaceutical applications of albumin-based drug delivery carriers, especially for the delivery of chemotherapeutic agents, has increased in recent years. Albumin has several advantages over synthetic polymers, as it is biocompatible, biodegradable, has low cytotoxicity and has an excellent binding capacity with various drugs. Micro- and nano-carriers not only protect active pharmaceutical ingredients against degradation, but also offer a prolonged release of drugs in a controlled fashion. Since existing tumour chemotherapeutic agents neither target tumour cells, nor are they specific to tumour cells, a slow release of drugs from carriers would be beneficial in targeting carcinogenic cells intracellularly. This article aims at providing an overview of pharmaceutical applications of albumin as a drug delivery carrier in tumour chemotherapy.
Export Options
About this article
Cite this article as:
Yasser Shahzad, Ikram Ullah Khan, Talib Hussain, Alamgeer, Christophe A. Serra, Syed A.A. Rizvi, Minja Gerber and Plessis du Jeanetta, Bioactive Albumin-Based Carriers for Tumour Chemotherapy, Current Cancer Drug Targets 2014; 14 (8) . https://dx.doi.org/10.2174/1568009614666141028100640
DOI https://dx.doi.org/10.2174/1568009614666141028100640 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Cutaneous Markers of HIV Infection and Progression
Current HIV Research mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Changes of Gene Expression in the Developing Brain by Acute Ethanol Exposure
Current Psychopharmacology P-glycoprotein as a Drug Target in the Treatment of Multidrug Resistant Cancer
Current Drug Targets Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Current Bioactive Compounds Identification of Sets of Cytoskeletal Related and Adhesion-related Coding Region Mutations in the TCGA Melanoma Dataset that Correlate with a Negative Outcome
Current Genomics Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents 1,2,4-Triazine Chemistry Part III: Synthetic Strategies to Functionalized Bridgehead Nitrogen Heteroannulated 1,2,4-Triazine Systems and their Regiospecific and Pharmacological Properties
Current Organic Synthesis Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer
Current Topics in Medicinal Chemistry Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways
Current Cancer Drug Targets Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry Low Molecular Weight and Oligomeric Chitosans and Their Bioactivities
Current Topics in Medicinal Chemistry Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents